Top considerations when determining whether to approve expensive drugs March 29, 2017 By Bryant Furlow Weighing the ethics of approving expensive cancer drugs for patients facing terminal disease is a multifaceted endeavor. Here are some recommendations. Payers strategize to manage opioid use March 28, 2017 By Tracey Walker How managed care organizations manage opioid utilization and some of the limitations to those management strategies was a hot topic at the AMCP Annual Meeting. Creating a ‘robust’ specialty pharmacy network March 28, 2017 By Tracey Walker The correct approach to take when creating a specialty pharmacy network is a key issue for healthcare executives. FDA approvals for specialty drugs to pick up in 2017 March 28, 2017 By Bryant Furlow Numerous specialty medications, generics, and biosimilars, are expected to be approved this year for cancer, inflammatory and autoimmune diseases, and other indications. State medical marijuana laws continue to expand March 28, 2017 By Bryant Furlow Medical marijuana’s therapeutic evidence base remains nascent and controversial but the regulatory landscape is evolving rapidly. Insulin treatment persistence varies among payers March 24, 2017 By Tracey Walker A study from Walgreens provides a benchmark of basal insulin treatment persistence across different payers in the United States. Five things to know about Trump’s FDA lead pick Gottlieb March 23, 2017 By Karen Appold On March 10, the White House announced that President Donald Trump selected Scott Gottlieb, MD, who has worked for FDA in the past, as his choice to head the FDA. Here are five things managed healthcare executives should know about the pick. Opinion: More industry-stakeholders play blame game for high drug costs March 22, 2017 By Devon Herrick PhD Our policy analyst weighs in on a new drug industry PR campaign that attempts to shift the blame for high drug costs. Five pharmacy regulations health execs must keep on their radars in 2017 March 18, 2017 By Kenneth Maxik Here are five critical regulations that executives can begin to prepare for today. What more transparency at the FDA means for health executives March 18, 2017 By Tracey Walker Researchers create a set of recommendations for transparency at the agency in five principal areas.